title: EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
abstract: OBJECTIVE
  The validity of the three currently used chronic myeloid leukemia (CML) scoring systems (Sokal CML prognostic scoring system, Euro/Hasford CML scoring system, and the EUTOS CML prognostic scoring system) were compared in the CML patients receiving frontline imatinib mesylate.
  
  
  METHODS
  One hundred and fourty-three chronic phase CML patients (71 males, 72 females) taking imatinib as frontline treatment were included in the study. The median age was 44 (16-82) years. Median total and on-imatinib follow-up durations were 29 (3.8-130) months and 25 (3-125) months, respectively.
  
  
  RESULTS
  The complete hematological response (CHR) rate at 3 months was 95%. The best cumulative complete cytogenetic response (CCyR) rate at 24 months was 79.6%. Euro/Hasford scoring system was well-correlated with both Sokal and EUTOS scores (r = 0.6, P < 0.001 and r = 0.455, P < 0.001). However, there was only a weak correlation between Sokal and EUTOS scores (r = 0.2, P = 0.03). The 5-year median estimated event-free survival for low and high EUTOS risk patients were 62.6 (25.7-99.5) and 15.3 (7.4-23.2) months, respectively (P < 0.001). This performance was better than Sokal (P = 0.3) and Euro/Hasford (P = 0.04) scoring systems. Overall survival and CCyR rates were also better predicted by the EUTOS score.
  
  
  CONCLUSIONS
  EUTOS CML prognostic scoring system, which is the only prognostic system developed during the imatinib era, predicts European LeukemiaNet (ELN)-based event-free survival better than Euro/Hasford and Sokal systems in CML patients receiving frontline imatinib mesylate. This observation might have important clinical implications.
authors.affiliation: Hacettepe University, Ankara, Turkey.
authors.forename: Burak
authors.initials: B
authors.lastname: Uz
authors.forename: Yahya
authors.initials: Y
authors.lastname: Buyukasik
authors.forename: Hilmi
authors.initials: H
authors.lastname: Atay
authors.forename: Engin
authors.initials: E
authors.lastname: Kelkitli
authors.forename: Mehmet
authors.initials: M
authors.lastname: Turgut
authors.forename: Ozlen
authors.initials: O
authors.lastname: Bektas
authors.forename: Eylem
authors.initials: E
authors.lastname: Eliacik
authors.forename: Ayşe
authors.initials: A
authors.lastname: Isik
authors.forename: Salih
authors.initials: S
authors.lastname: Aksu
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
authors.forename: Nilgun
authors.initials: N
authors.lastname: Sayinalp
authors.forename: Osman I
authors.initials: OI
authors.lastname: Ozcebe
authors.forename: Ibrahim C
authors.initials: IC
authors.lastname: Haznedaroglu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate